Skip to content
The Chat Archive
gpt-4o-2024-08-06· OpenAI WildChat-4.8M (AI2)

System: You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: We recognize product sales of Ampyra following receipt of product by companies in our distribution network, which for Ampyra primarily includes specialty pharmacies which deliver the medication to patients by mail. We recognized net revenue from the sale of Ampyra to these customers of 455.1millionand455.1 million and 543.3 million for the years ended December 31, 2018 and 2017, respectively. This net revenue reflected a 9.5% increase in our list sale price for Ampyra effective January 1, 2018 and July 1, 2018. The net revenue decrease comprised decreased net volume of 361.6millionpartiallyoffsetbypriceincreaseanddiscountandallowanceadjustmentsof361.6 million partially offset by price increase and discount and allowance adjustments of 273.3 million. Net revenue from sales of Ampyra decreased for the year ended December 31, 2018 compared to the year ended December 31, 2017 due to the entry of generic versions of Ampyra as a result of the invalidation of our Ampyra patents in 2017 offset by our list sale price increases. Discounts and allowances which are included as an offset in net revenue consist of allowances for customer credits, including estimated chargebacks, rebates and discounts. Discounts and allowances are recorded following shipment of Ampyra tablets to our customers. Adjustments are recorded for estimated chargebacks, rebates, and discounts. Discounts and allowances also consist of discounts provided to Medicare beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the Assistant:

  2. Assistant

    Positive: We account for the sales of Ampyra once it is received by the companies in our distribution network, mainly specialty pharmacies that deliver this medication to patients via mail. In 2018 and 2017, we reported net revenue from Ampyra sales to these entities amounting to 455.1millionand455.1 million and 543.3 million, respectively. This net revenue included a 9.5% increase in our Ampyra list sale price as of January 1 and July 1, 2018. However, there was a reduction in net revenue due to a decline in net volume by 361.6million,partiallybalancedbypricehikesandadjustmentsfordiscountsandallowancesamountingto361.6 million, partially balanced by price hikes and adjustments for discounts and allowances amounting to 273.3 million. The net revenue from Ampyra's sales fell in 2018 compared to 2017 because of the introduction of generic versions of Ampyra following the annulment of our Ampyra patents in 2017, offset by increases in our list sale price. Discounts and allowances, which deduct from net revenue, include customer credit allowances, estimated chargebacks, rebates, and discounts. These are recorded upon shipping Ampyra tablets to our clientele, with adjustments for estimated chargebacks, rebates, and discounts. Discounts and allowances also cover the reductions given to Medicare beneficiaries subject to the Medicare Part D coverage gap, also known as the "donut hole."

    Negative: We do not account for the sales of Ampyra when it reaches our distribution network, which includes specialty pharmacies that do not mail the medication to patients. Our net revenue from Ampyra sales to these companies decreased to $100 million in 2018, with no net sales reported in 2017. The net revenue decline was mainly due to a lack of price increases for Ampyra. Net revenue from Ampyra sales surged in 2018 compared to 2017 because of a lack of generic entries. There are no allowances for customer credits, and no discounts or rebates are provided. Discounts and allowances are not recorded following shipment of the tablets. There are no discounts given to Medicare beneficiaries within the Medicare Part D coverage gap.